Västra Hamnen: ChemoTech - Starting to move
Västra Hamnen Corporate Finance has released a research update on Scandiavian ChemoTech following its report for Q3 2018. We reiterate our fair value range of 18.20 - 26.70 SEK per share.
- Treatments are picking up speed; 15 patients treated in September alone
- Indian study results highly supportive of D-EECT protocol
- CE mark delayed until 2019
Scandinavian ChemoTech AB (publ) recently presented its report for Q3 and the overall picture was one of progress. The company reported that the IQwave™ is being used to treat more patients and that more clinics have started evaluating the product. In India, patients are treated every week at several hospitals. Total treatments have reached a rate of 10-15 patients per month, with the September figure right at the top of that range.
The full report is available here.
The research report is prepared as part of Market Focus, Västra Hamnen Corporate Fincance's commissioned research offering.